Nuvectis Pharma, Inc.(NVCT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

NVCT Nuvectis Pharma, Inc.

Post-Mkt 07-28 18:27:06 EDT

19.82

+0.28

+1.43%

盘后19.82

+0.000.00%

16:10 EDT

High20.00	Low19.00	Vol195.50K
Open19.85	D1 Closing19.54	Amplitude5.12%
Mkt Cap624.84M	Tradable Cap399.91M	Total Shares31.53M
T/O3.82M	T/O Rate0.97%	Tradable Shares20.18M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"NVCT","market":"US","secType":"STK","nameCN":"Nuvectis Pharma, Inc.","latestPrice":19.82,"timestamp":1785268800000,"preClose":19.54,"halted":0,"volume":195499,"hourTrading":{"tag":"盘后","latestPrice":19.82,"preClose":19.82,"latestTime":"16:10 EDT","volume":8,"amount":158.56,"timestamp":1785269404980,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.014329580348004153,"floatShares":20177171,"shares":31525500,"eps":-1.304517,"marketStatus":"Post-Mkt","change":0.28,"latestTime":"07-28 18:27:06 EDT","open":19.85,"high":20,"low":19,"amount":3818050,"amplitude":0.051177,"askPrice":19.82,"askSize":50,"bidPrice":18.3,"bidSize":500,"shortable":3,"etf":0,"ttmEps":-1.304517,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1785283200000},"marketStatusCode":4,"adr":0,"listingDate":1638334800000,"exchange":"NASDAQ","adjPreClose":19.54,"postHourTrading":{"tag":"盘后","latestPrice":19.82,"preClose":19.82,"latestTime":"16:10 EDT","volume":8,"amount":158.56,"timestamp":1785269404980,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.908143,"impliedVol":2.0944,"impliedVolPercentile":0.7729},"requestUrl":"/m/hq/s/NVCT/wiki","defaultTab":"wiki","newsList":[{"id":"2653354410","title":"Maxim Group Keeps Their Buy Rating on Nuvectis Pharma (NVCT)","url":"https://stock-news.laohu8.com/highlight/detail?id=2653354410","media":"TIPRANKS","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653354410?lang=en_us&edition=fundamental","pubTime":"2026-07-24 23:36","pubTimestamp":1784907412,"startTime":"0","endTime":"0","summary":"In a report released yesterday, Naz Rahman from Maxim Group reiterated a Buy rating on Nuvectis Pharma, with a price target of $30.00. Rahman cover...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/maxim-group-keeps-their-buy-rating-on-nuvectis-pharma-nvct-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/maxim-group-keeps-their-buy-rating-on-nuvectis-pharma-nvct-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NVCT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653724055","title":"Nuvectis’ NXP100 Just Achieved the First Marketing Approval Ever for a Once-Daily Oral Factor B Inhibitor","url":"https://stock-news.laohu8.com/highlight/detail?id=2653724055","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653724055?lang=en_us&edition=fundamental","pubTime":"2026-07-24 00:30","pubTimestamp":1784824232,"startTime":"0","endTime":"0","summary":"WSW, NY, July 23rd, 2026, FinanceWire Nuvectis Pharma (NASDAQ:NVCT) announced this morning that ciprocopan (NXP100) has been approved by China’s Na...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/newswire/nuvectis-nxp100-just-achieved-the-first-marketing-approval-ever-for-a-once-daily-oral-factor-b-inhibitor?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/newswire/nuvectis-nxp100-just-achieved-the-first-marketing-approval-ever-for-a-once-daily-oral-factor-b-inhibitor?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IYW","PSQ","QQQE","SQQQ","QQQM","TQQQ","JEPQ","NVCT",".IXIC","QQQ","ONEQ","NDX","MNQmain","TECS","QDTE","QQQA","QYLG","QLD","NVIW.SI","TQQY","QQQY","QQQJ","BK4139","NQmain","FTEC","GPIQ","QID"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653721454","title":"Pantginis Reiterates Buy on Nuvectis, Citing Ciprocopan Approval and Pipeline Diversification; Price Target Maintained at $39","url":"https://stock-news.laohu8.com/highlight/detail?id=2653721454","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653721454?lang=en_us&edition=fundamental","pubTime":"2026-07-23 23:25","pubTimestamp":1784820328,"startTime":"0","endTime":"0","summary":"Joseph Pantginis, an analyst from H.C. Wainwright, reiterated the Buy rating on Nuvectis Pharma. The associated price target remains the same with ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/pantginis-reiterates-buy-on-nuvectis-citing-ciprocopan-approval-and-pipeline-diversification-price-target-maintained-at-39-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/pantginis-reiterates-buy-on-nuvectis-citing-ciprocopan-approval-and-pipeline-diversification-price-target-maintained-at-39-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NVCT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653723504","title":"Nuvectis Pharma Says Paroxysmal Nocturnal Hemoglobinuria Drug Approved by Chinese Regulator","url":"https://stock-news.laohu8.com/highlight/detail?id=2653723504","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653723504?lang=en_us&edition=fundamental","pubTime":"2026-07-23 21:07","pubTimestamp":1784812063,"startTime":"0","endTime":"0","summary":"Nuvectis Pharma  said Thursday that ciprocopan, also known as NXP100, has received marketing approval from the National Medicinal Products Administration of China for the treatment of patients with Paroxysmal Nocturnal Hemoglobinuria who had previously been untreated with Complement inhibitors.China-based Haisco developed the drug and handles its development, regulatory approvals, and commercialization in the country, while Nuvectis holds exclusive rights to develop and commercialize ciprocopan outside of Greater China, India, and certain Southeast Asian countries, Nuvectis said.The approval was based on a late-stage study by Haisco that demonstrated ciprocopan's superiority over eculizumab in patients with Paroxysmal Nocturnal Hemoglobinuria who had previously not been treated with Complement inhibitors, the statement said.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["NVCT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653728798","title":"Nuvectis Corrects Title of Ciprocopan China Marketing Approval Release","url":"https://stock-news.laohu8.com/highlight/detail?id=2653728798","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653728798?lang=en_us&edition=fundamental","pubTime":"2026-07-23 21:01","pubTimestamp":1784811661,"startTime":"0","endTime":"0","summary":"Nuvectis corrects title of ciprocopan China marketing approval releaseNuvectis issued a correction to its release, changing only the title.Corrected title states ciprocopan (NXP100) won China marketin","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260723:nNDL3xlSXb:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B3QW5Z07.USD","SG9999014039.USD","BCDF","IE00BN0W2T93.GBP","BK4588","IE00BN0W2V16.EUR","LU0314104364.USD","SG9999014013.SGD","IE00B64PRP62.GBP","LU2210150020.SGD","NVCT","BK4139","SG9999014021.USD","LU2210149790.SGD","NDAQ","LU2095319765.USD","BK4585","IE00BKPKM429.USD","BK4112","IE00BN0W2W23.USD","SG9999014005.SGD","IE00BGHQF748.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653574758","title":"Nuvectis Pharma receives marketing approval in China for ciprocopan","url":"https://stock-news.laohu8.com/highlight/detail?id=2653574758","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653574758?lang=en_us&edition=fundamental","pubTime":"2026-07-23 19:45","pubTimestamp":1784807123,"startTime":"0","endTime":"0","summary":"Nuvectis Pharma (NVCT) announced that ciprocopan, a once-daily oral complement Factor B inhibitor, received marketing approval from the National Me...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/nuvectis-pharma-receives-marketing-approval-in-china-for-ciprocopan-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/nuvectis-pharma-receives-marketing-approval-in-china-for-ciprocopan-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NVCT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653742517","title":"Nuvectis Says China Regulator Approves Ciprocopan for Treatment-naive PNH Patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2653742517","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653742517?lang=en_us&edition=fundamental","pubTime":"2026-07-23 19:32","pubTimestamp":1784806339,"startTime":"0","endTime":"0","summary":"Nuvectis says China regulator approves ciprocopan for treatment-naive PNH patientsNuvectis partner Haisco secured China NMPA marketing clearance for ciprocopan (NXP100) in treatment-naive paroxysmal n","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260723:nNDL7gXz26:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4112","BCDF","BK4588","IE00BGHQF748.EUR","SG9999014039.USD","IE00B64PRP62.GBP","BK0077","SG9999014021.USD","IE00B3QW5Z07.USD","BK0028","002653","BK0239","LU2210150020.SGD","LU2210149790.SGD","IE00BN0W2W23.USD","LU2095319765.USD","NVCT","IE00BN0W2T93.GBP","NDAQ","SG9999014013.SGD","SG9999014005.SGD","BK4585","BK0188","BK4139","BK0033","IE00BN0W2V16.EUR","IE00BKPKM429.USD","LU0314104364.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653742331","title":"Nuvectis Pharma - Ciprocopan (nxp100) Receives Marketing Approval in China for Treatment-naive Pnh Patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2653742331","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653742331?lang=en_us&edition=fundamental","pubTime":"2026-07-23 19:30","pubTimestamp":1784806200,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260723:nTUA6R8QGV:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NVCT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650975043","title":"Nuvectis Pharma’s NXP900 Combo Trial Adds Fresh Momentum to NVCT in EGFR Lung Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2650975043","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2650975043?lang=en_us&edition=fundamental","pubTime":"2026-07-10 00:32","pubTimestamp":1783614746,"startTime":"0","endTime":"0","summary":"Nuvectis Pharma, Inc. ($NVCT) announced an update on their ongoing clinical study. The Phase 1b clinical study titled “A Phase 1b Clinical Study of...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/nuvectis-pharmas-nxp900-combo-trial-adds-fresh-momentum-to-nvct-in-egfr-lung-cancer?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/nuvectis-pharmas-nxp900-combo-trial-adds-fresh-momentum-to-nvct-in-egfr-lung-cancer?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","NVCT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650929000","title":"The Billion-Dollar Pill: With NXP100, Nuvectis Pharma Just Staked Its Claim in the New Biotech Gold Rush","url":"https://stock-news.laohu8.com/highlight/detail?id=2650929000","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2650929000?lang=en_us&edition=fundamental","pubTime":"2026-07-09 20:00","pubTimestamp":1783598415,"startTime":"0","endTime":"0","summary":"WSW, NY, July 9th, 2026, FinanceWire In June, Nuvectis Pharma (NASDAQ:NVCT) signed a deal that took it from a single-drug oncology company to the o...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/newswire/the-billion-dollar-pill-with-nxp100-nuvectis-pharma-just-staked-its-claim-in-the-new-biotech-gold-rush?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/newswire/the-billion-dollar-pill-with-nxp100-nuvectis-pharma-just-staked-its-claim-in-the-new-biotech-gold-rush?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PSQ",".IXIC","NDX","BK4139","ONEQ","BK4585","NVIW.SI","QDTE","BK4581","NVCT","JEPQ","QQQM","TQQY","QLD","MNQmain","QQQA","QQQY","QYLG","QID","QQQE","TQQQ","SQQQ","GPIQ","TECS","QQQ","NQmain","QQQJ","BK4588","XBI","IYW","FTEC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649640686","title":"Nuvectis Pharma is Maintained at Buy by Roth Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2649640686","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649640686?lang=en_us&edition=fundamental","pubTime":"2026-07-06 17:29","pubTimestamp":1783330140,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/NVCT/analyst-ratings(END) Dow Jones NewswiresJuly 06, 2026 05:29 ET","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NVCT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649140846","title":"Nuvectis Pharma price target raised to $33 from $20 at Roth Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2649140846","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649140846?lang=en_us&edition=fundamental","pubTime":"2026-07-06 09:00","pubTimestamp":1783299606,"startTime":"0","endTime":"0","summary":"Roth Capital raised the firm’s price target on Nuvectis Pharma (NVCT) to $33 from $20 and keeps a Buy rating on the shares. The company “significan...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/nuvectis-pharma-price-target-raised-to-33-from-20-at-roth-capital-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/nuvectis-pharma-price-target-raised-to-33-from-20-at-roth-capital-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NVCT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648157362","title":"Insiders Make Bold Move as Nuvectis Pharma Leadership Ramps Up Buying Spree","url":"https://stock-news.laohu8.com/highlight/detail?id=2648157362","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2648157362?lang=en_us&edition=fundamental","pubTime":"2026-07-02 10:04","pubTimestamp":1782957872,"startTime":"0","endTime":"0","summary":"New insider activity at Nuvectis Pharma ( ($NVCT) ) has taken place on July 1, 2026. Nuvectis Pharma has seen notable insider buying activity, with...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/insider-trading/insiders-make-bold-move-as-nuvectis-pharma-leadership-ramps-up-buying-spree-insider-trading-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/insider-trading/insiders-make-bold-move-as-nuvectis-pharma-leadership-ramps-up-buying-spree-insider-trading-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NVCT","BK4139","SHAP.U"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648540298","title":"Nuvectis Pharma Chairman, CEO Ron Bentsur Buys USD 250,000 Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2648540298","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2648540298?lang=en_us&edition=fundamental","pubTime":"2026-07-02 01:40","pubTimestamp":1782927656,"startTime":"0","endTime":"0","summary":"Nuvectis Pharma Chairman, CEO Ron Bentsur buys USD 250,000 common sharesNuvectis Pharma Chairman and CEO Ron Bentsur bought 12,500 common shares at USD 20 each in a public offering.His direct benefici","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260701:nNDL33gW1F:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Nuvectis Pharma Chairman, CEO Ron Bentsur Buys USD 250,000 Common Shares","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","NVCT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647556528","title":"Concentrix Reports Downbeat Q2 Earnings, Joins Nuvectis Pharma, Vishay Intertechnology And Other Big Stocks Moving Lower In Tuesday’s Pre-Market Session","url":"https://stock-news.laohu8.com/highlight/detail?id=2647556528","media":"Benzinga_recent_news","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647556528?lang=en_us&edition=fundamental","pubTime":"2026-06-30 20:03","pubTimestamp":1782820980,"startTime":"0","endTime":"0","summary":"US stock futures up, Dow futures gain 100+ points. Concentrix Corp (CNXC) shares down 24% after weak Q2 results and lowered FY26 guidance. Other stocks also decline in pre-market trading.","market":"hk","thumbnail":"https://cdn.benzinga.com/cdn-cgi/image/width=240,format=auto,quality=85/files/images/story/2026/06/30/Konskie--Poland---August-14--2025-Concen.jpg","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/cdn-cgi/image/width=240,format=auto,quality=85/files/images/story/2026/06/30/Konskie--Poland---August-14--2025-Concen.jpg"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/trading-ideas/movers/26/06/60182200/concentrix-reports-downbeat-q2-earnings-joins-nuvectis-pharma-vishay-intertechnology-and-other-big-stocks-moving-lower-in-tuesdays-pre-market-session","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/trading-ideas/movers/26/06/60182200/concentrix-reports-downbeat-q2-earnings-joins-nuvectis-pharma-vishay-intertechnology-and-other-big-stocks-moving-lower-in-tuesdays-pre-market-session","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_recent_news","symbols":["VSH","NVCT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647258558","title":"Nuvectis Pharma Tumbles on Deep-discounted $100 Mln Share Sale","url":"https://stock-news.laohu8.com/highlight/detail?id=2647258558","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647258558?lang=en_us&edition=fundamental","pubTime":"2026-06-30 19:40","pubTimestamp":1782819643,"startTime":"0","endTime":"0","summary":"BUZZ-Nuvectis Pharma tumbles on deep-discounted $100 mln share sale** Shares of Nuvectis PharmaNVCT.Odown 22% to $22.25 before the bell after $100 mln follow-on offering priced** NVCT late Mon sold 5 mln shares at $20, a 30% discount to their record-high close of $28.53** Cantor Fitzgerald sole bookrunner** Fort Lee, New Jersey-based NVCT, which has 26.5 mln shares outstanding, intends to use net offering proceeds to advance programs of NXP100, NXP200, and NXP900 or any future product candidate, among other purposes** On Jun 22, NVCT said itsecured licensing dealwith China's Haisco002653.SZfor experimental drugs NXP100 and NXP200, targeting complement-mediated diseases and cancer to broaden its pipeline** NVCT shares have nearly tripled this month through Mon** All 5 analysts rate the shares  \"buy\" and their median PT is $30, per LSEG data","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260630:nL6N4320P6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0077","BK0033","BK4139","BK0028","BK0188","002653","BK0239","NVCT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647755810","title":"Top Premarket Decliners","url":"https://stock-news.laohu8.com/highlight/detail?id=2647755810","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647755810?lang=en_us&edition=fundamental","pubTime":"2026-06-30 19:35","pubTimestamp":1782819325,"startTime":"0","endTime":"0","summary":"Unicycive Therapeutics  shares were down 37% in Tuesday premarket activity, following the previous session's 8% gain.GMEX Robotics  stock was down 34% after the company said it would implement a 1-for-9 share consolidation of its Class A and Class B ordinary shares.Universe Pharmaceuticals  shares were down 29% after the previous session's 311% rally.Nuvectis Pharma  stock was down 24% after the company priced a secondary offering of 5 million common shares at $20 per share.Decoy Therapeutics  shares were down 21%, following the earlier session's 74% gain.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["UNCY","DCOY","GMEX","BK4200","NVCT","BK4139","BK4539","UPC","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647458985","title":"Nuvectis Pharma Prices 5 Million-share Offering at $20, Raising $100 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2647458985","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647458985?lang=en_us&edition=fundamental","pubTime":"2026-06-30 10:30","pubTimestamp":1782786617,"startTime":"0","endTime":"0","summary":"Nuvectis Pharma prices 5 million-share offering at $20, raising $100 millionNuvectis priced an underwritten public offering of 5,000,000 common shares at USD 20 per share.Gross proceeds expected at US","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260630:nNDL80JYZM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014021.USD","BK4585","BK4588","LU2095319765.USD","IE00BN0W2T93.GBP","SG9999014005.SGD","BK4112","IE00BN0W2V16.EUR","IE00B3QW5Z07.USD","IE00BN0W2W23.USD","SG9999014039.USD","NVCT","LU0314104364.USD","LU2210150020.SGD","IE00B64PRP62.GBP","SG9999014013.SGD","NDAQ","BK4139","IE00BGHQF748.EUR","IE00BKPKM429.USD","LU2210149790.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647307702","title":"Nuvectis Pharma TBA Spot Secondary; price range $20.00-$22.00","url":"https://stock-news.laohu8.com/highlight/detail?id=2647307702","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647307702?lang=en_us&edition=fundamental","pubTime":"2026-06-30 05:50","pubTimestamp":1782769811,"startTime":"0","endTime":"0","summary":"Cantor Fitzgerald is acting as sole book running manager for the offering. Published first on TheFly – the ultimate source for real-time, market-mo...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/nuvectis-pharma-tba-spot-secondary-price-range-20-00-22-00-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/nuvectis-pharma-tba-spot-secondary-price-range-20-00-22-00-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","NVCT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647304292","title":"Nuvectis Pharma - Lowers Sales Agreement Prospectus Amount to $5 Mln as of June 29, 2026 - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2647304292","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647304292?lang=en_us&edition=fundamental","pubTime":"2026-06-30 04:14","pubTimestamp":1782764071,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260629:nFWN43115Q:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NVCT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.nuvectis.com","stockEarnings":[{"period":"1week","weight":0.0837},{"period":"1month","weight":-0.2814},{"period":"3month","weight":1.2486},{"period":"6month","weight":1.3345},{"period":"1year","weight":1.5116},{"period":"ytd","weight":1.5881}],"compareEarnings":[{"period":"1week","weight":-0.004},{"period":"1month","weight":0.0139},{"period":"3month","weight":0.0385},{"period":"6month","weight":0.0628},{"period":"1year","weight":0.1601},{"period":"ytd","weight":0.0838}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Nuvectis Pharma, Inc., a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. The company's lead product candidate is NXP800, a novel small molecule that is in Phase 1b clinical trials for the treatment of patients with platinum-resistant, ARID1a-mutated ovarian carcinoma. It is also developing NXP900, a small molecule drug candidate, which is in Phase 1a clinical trails that inhibits the Proto-oncogene c-Src and YES1 kinases. It has license agreement with the CRT Pioneer Fund for the NXP800 and any of related derivatives; and the University of Edinburgh for the NXP900 and any of associated derivatives. The company was formerly known as Centry Pharma, Inc. and changed its name to Nuvectis Pharma, Inc. in July 2021. Nuvectis Pharma, Inc. was incorporated in 2020 and is based in Fort Lee, New Jersey.","yearOnYearQuotes":[{"month":1,"riseRate":0.75,"avgChangeRate":0.130119},{"month":2,"riseRate":0.75,"avgChangeRate":0.147062},{"month":3,"riseRate":0.6,"avgChangeRate":0.077847},{"month":4,"riseRate":0.8,"avgChangeRate":0.055849},{"month":5,"riseRate":0.8,"avgChangeRate":0.192364},{"month":6,"riseRate":0.2,"avgChangeRate":0.054549},{"month":7,"riseRate":0.4,"avgChangeRate":-0.067418},{"month":8,"riseRate":0.5,"avgChangeRate":-0.005612},{"month":9,"riseRate":0,"avgChangeRate":-0.100626},{"month":10,"riseRate":0.5,"avgChangeRate":-0.011793},{"month":11,"riseRate":0.25,"avgChangeRate":-0.090389},{"month":12,"riseRate":0.75,"avgChangeRate":0.071233}],"exchange":"NASDAQ","name":"Nuvectis Pharma, Inc.","nameEN":"Nuvectis Pharma, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.46.0","shortVersion":"4.46.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Nuvectis Pharma, Inc.(NVCT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Nuvectis Pharma, Inc.(NVCT) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Nuvectis Pharma, Inc.,NVCT,Nuvectis Pharma, Inc.股票,Nuvectis Pharma, Inc.股票老虎,Nuvectis Pharma, Inc.股票老虎国际,Nuvectis Pharma, Inc.行情,Nuvectis Pharma, Inc.股票行情,Nuvectis Pharma, Inc.股价,Nuvectis Pharma, Inc.股市,Nuvectis Pharma, Inc.股票价格,Nuvectis Pharma, Inc.股票交易,Nuvectis Pharma, Inc.股票购买,Nuvectis Pharma, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Nuvectis Pharma, Inc.(NVCT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Nuvectis Pharma, Inc.(NVCT) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}